Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.




How to identify if you need outside expertise for Active Pharmaceutical Ingredient (API) development
Philip Payne, 13 April 2017

Your API strategy: How to identify if you need additional resource  Your API fuels your drug development program, which is likely to suffer if you allow it to become depleted. It is, of course, advisable therefore to consider whether you have the resources to synthesize the quantities of the API required for your development program to move...

Integrating Active Pharmaceutical Ingredient program into drug discovery and drug development
Zadeo Cimarosti, 30 March 2017

Integrating API – Not limited to drug development Both drug discovery and drug development are critical to the identification of novel medicines that may at one point in the future have a significant impact on global health. There are many variables that go into the processes, such as the defining of biological properties of the compound lead,...

Technology transfer in Active Pharmaceutical Ingredient (API) strategy
Zadeo Cimarosti, 13 March 2017

The challenges of technology transfer in API When it comes to optimizing your API strategy, technology transfer can mean different things to different people. It can either refer to the transfer of the process (together with its documentation) between product development to manufacture, or it can mean the transfer between manufacturing sites –...

Avoiding analytical disasters in developing an API strategy
Mike Cole, 3 March 2017

Avoiding common analytical disasters in developing your API strategy during drug development

How de-risking strategies in API development can improve efficiencies and increase chances of success
Stephen Gorsuch, 20 February 2017

Managing the risks of your Active Pharmaceutical Ingredient (API) strategy Drug development is a risky venture, to say the least. With a proportionally small number of potential leads making it through even to clinical trials, de-risking is an important step in any API strategy. There can be a plethora of routes to taking a drug through the...



Contact us


Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308